Neurochemical Research

, Volume 36, Issue 2, pp 327–338 | Cite as

The Effects of Antidepressants on Mitochondrial Function in a Model Cell System and Isolated Mitochondria



The in vitro effects of antidepressant drugs on mitochondrial function were investigated in a CHOβ2SPAP cell line used previously to determine the effects of antidepressants on gene transcription (Abdel-Razaq et al., Biochem Pharmacol 73:1995–2003, 2007) and in rat heart isolated mitochondria. Apoptotic effects of clomipramine (CLOM), desipramine (DMI) and of norfluoxetine (NORF, the active metabolite of fluoxetine), on cellular viability were indicated by morphological changes and concentration-dependent increases in caspase-3 activity in CHO cells after 18 h exposure to CLOM, DMI and NORF. However, tianeptine (TIAN) was without effect. CLOM and NORF both reduced integrated mitochondrial function as shown by marked reductions in membrane potential (MMP) in mitochondria isolated from rat hearts. DMI also showed a similar but smaller effect, whereas, TIAN did not elicit any significant change in MMP. Moreover, micromolar concentrations of CLOM, DMI and NORF caused significant inhibitions of the activities of mitochondrial complexes (I, II/III and IV). The inhibitory effects on complex IV activity were most marked. TIAN inhibited only complex I activity at concentrations in excess of 20 μM. The observed inhibitory effects of antidepressants on the mitochondrial complexes were accompanied by a significant decrease in the mitochondrial state-3 respiration at concentrations above 10 μM. The results demonstrate that the apoptotic cell death observed in antidepressant-treated cells could be due to disruption of mitochondrial function resulting from multiple inhibition of mitochondrial enzyme complexes. The possibility that antimitochondrial actions of antidepressants could provide a potentially protective pre-conditioning effect is discussed.


Antidepressants Mechanism of action Mitochondrial dysfunction Mitochondrial complexes Apoptosis Caspase-3 



The authors are grateful for the support of the Hashemite University (Jordan) and the University of Nottingham (UK).


  1. 1.
    Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M (2006) Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 58:115–134CrossRefPubMedGoogle Scholar
  2. 2.
    Manfredi G, Beal MF (2000) The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain Pathol 10:462–472CrossRefPubMedGoogle Scholar
  3. 3.
    Naoi M, Yi H, Shamoto-Nagai M, Akao Y, Maruyama W, Tanaka M (2005) Oxidative stress in mitochondria: decision to survival and death of neurons in neurodegenerative disorders. Mol Neurobiol 31:81–93CrossRefPubMedGoogle Scholar
  4. 4.
    Orth M, Schapira AH (2001) Mitochondria and degenerative disorders. Am J Med Genet 106:27–36CrossRefPubMedGoogle Scholar
  5. 5.
    Wittenhagen LM, Kelley SO (2002) Dimerization of a pathogenic human mitochondrial tRNA. Nat Struct Biol 9:586–590PubMedGoogle Scholar
  6. 6.
    Bates TE, Heales SJ, Davies SE, Boakye P, Clark JB (1994) Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria: evidence for a primary involvement of energy depletion. J Neurochem 63:640–648CrossRefPubMedGoogle Scholar
  7. 7.
    Calabrese V, Bates TE, Stella AM (2000) NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem Res 25:1315–1341CrossRefPubMedGoogle Scholar
  8. 8.
    Wallace DC (1999) Mitochondrial diseases in man and mouse. Science 283:1482–1488CrossRefPubMedGoogle Scholar
  9. 9.
    Sammut IA, Jayakumar J, Latif N, Rothery S, Severs NJ, Smolenski RT, Bates TE, Yacoub MH (2001) Heat stress contributes to the enhancement of cardiac mitochondrial complex activity. Am J Pathol 158:1821–1831PubMedGoogle Scholar
  10. 10.
    Odawara M (2002) Mitochondrial gene abnormalities as a cause of psychiatric diseases. Nucleic Acids Symp Ser 2:253–254Google Scholar
  11. 11.
    Wallace DC (1992) Diseases of the mitochondrial DNA. Annu Rev Biochem 61:1175–1212CrossRefPubMedGoogle Scholar
  12. 12.
    Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S (2004) Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 61:300–308CrossRefPubMedGoogle Scholar
  13. 13.
    Gardner A, Boles RG (2010) Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry (in press)Google Scholar
  14. 14.
    Kato T, Kato N (2000) Mitochondrial dysfunction in bipolar disorder. Bipolar Disorders 2:180–190CrossRefPubMedGoogle Scholar
  15. 15.
    Deicken RF, Weiner MW, Fein G (1995) Decreased temporal lobe phosphomonoesters in bipolar disorder. J Affect Disord 33:195–199CrossRefPubMedGoogle Scholar
  16. 16.
    Kato T, Inubushi T, Takahashi S, Shioiri T (1993) Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J Affect Disord 27:53–59CrossRefPubMedGoogle Scholar
  17. 17.
    Daley E, Wilkie D, Loesch A, Hargreaves IP, Kendall DA, Pilkington GJ, Bates TE (2005) Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun 328:623–632CrossRefPubMedGoogle Scholar
  18. 18.
    Iwamoto K, Bundo M, Kato T (2005) Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 14:241–253CrossRefPubMedGoogle Scholar
  19. 19.
    Munakata K, Kato T, Iwamoto K, Bundo M (2005) Mitochondrial DNA 3243A > G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol Psychiatry 57:525–532CrossRefPubMedGoogle Scholar
  20. 20.
    Abdel-Razaq W, Bates TE, Kendall DA (2007) The effects of antidepressants on cyclic AMP-response element-driven gene transcription in a model cell system. Biochem Pharmacol 73:1995–2003CrossRefPubMedGoogle Scholar
  21. 21.
    Otczyk M, Mulik K, Budziszewska B, Jaworska-Feil L, Basta-Kaim A, Kubera M, Jagla G, Nowak W, Lason W (2008) Effect of some antidepressants on the low corticosterone concentration-induced gene transcription in LMCAT fibroblast cells. J Physiol Pharmacol 59:153–162PubMedGoogle Scholar
  22. 22.
    Pariante CM, Kim RB, Makoff A, Kerwin RW (2003) Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol 139:1111–1118CrossRefPubMedGoogle Scholar
  23. 23.
    Richards JK, Abdel-Razaq W, Bates TE, Kendall DA (2005) The effects of desmethylimipramine on cyclic AMP-stimulated gene transcription in a model cell system. Biochem Pharmacol 70:762–769CrossRefPubMedGoogle Scholar
  24. 24.
    Karlsson H, Gu Y, DePierre J, Nassberger L (1998) Induction of apoptosis in proliferating lymphocytes by tricyclic antidepressants. Apoptosis 3:255–260CrossRefPubMedGoogle Scholar
  25. 25.
    Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M, Weizman A (2005) Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p–c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci 27:29–42CrossRefPubMedGoogle Scholar
  26. 26.
    Xia Z, Lundgren B, Bergstrand A, DePierre JW, Nassberger L (1999) Changes in the generation of reactive oxygen species and in mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clomipramine, and citalopram and the effects on these changes by Bcl-2 and Bcl-X(L). Biochem Pharmacol 57:1199–1208CrossRefPubMedGoogle Scholar
  27. 27.
    Lee JM, Peuler JD (2001) A possible indirect sympathomimetic action of metformin in the arterial vessel wall of spontanously hypertensive rats. Life Sci 69:1085–1092CrossRefPubMedGoogle Scholar
  28. 28.
    Li YF, Luo ZP (2002) Desipramine antagonized corticosterone-induced apoptosis in cultured PC12 cells. Acta Pharmacol Sin 23:311–314PubMedGoogle Scholar
  29. 29.
    Lucassen PJ, Fuchs E, Czeh B (2004) Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry 55:789–796CrossRefPubMedGoogle Scholar
  30. 30.
    McDonnell J, Latif ML, Rees ES, Bevan NJ, Hill SJ (1998) Influence of receptor number on the stimulation by salmeterol of gene transcription in CHO-K1 cells transfected with the human beta2-adrenoceptor. Br J Pharmacol 125:717–726CrossRefPubMedGoogle Scholar
  31. 31.
    Kristian T, Gertsch J, Bates TE, Siesjo BK (2000) Characteristics of the calcium-triggered mitochondrial permeability transition in nonsynaptic brain mitochondria: effect of cyclosporin A and ubiquinone O. J Neurochem 74:1999–2009CrossRefPubMedGoogle Scholar
  32. 32.
    Athanasiou A, Smith PA, Vakilpour S, Kumaran NM, Turner AE, Bagiokou D, Layfield R, Ray DE, Westwell AD, Alexander SP, Kendall DA, Lobo DN, Watson SA, Lophatanon A, Muir KA, Guo DA, Bates TE (2007) Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non-vanilloid receptor mediated cell death. Biochem Biophys Res Commun 354:50–55CrossRefPubMedGoogle Scholar
  33. 33.
    Bates TE, Almeida A, Heales SJ, Clark JB (1994) Postnatal development of the complexes of the electron transport chain in isolated rat brain mitochondria. Dev Neurosci 16:321–327CrossRefPubMedGoogle Scholar
  34. 34.
    Raspotnig G, Fauler G, Jantscher A, Windischhofer W, Schachl K, Leis HJ (1999) Colorimetric determination of cell numbers by Janus green staining. Anal Biochem 275:74–83CrossRefPubMedGoogle Scholar
  35. 35.
    Sandau KB, Callsen D, Brune B (1999) Protection against nitric oxide-induced apoptosis in rat mesangial cells demands mitogen-activated protein kinases and reduced glutathione. Mol Pharmacol 56:744–751PubMedGoogle Scholar
  36. 36.
    Martinou JC, Green DR (2001) Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2:63–67CrossRefPubMedGoogle Scholar
  37. 37.
    Stuart RA, Cyr DM, Neupert W (1994) Hsp70 in mitochondrial biogenesis: from chaperoning nascent polypeptide chains to facilitation of protein degradation. Experientia 50:1002–1011CrossRefPubMedGoogle Scholar
  38. 38.
    Eto K, Inoue B, Ogata M, Fukuda T, Araki Y (1985) Effect of tricyclic drugs on mitochondrial membrane. Acta Med Okayama 39:289–295PubMedGoogle Scholar
  39. 39.
    Katyare SS, Rajan RR (1995) Effect of long-term in vivo treatment with imipramine on the oxidative energy metabolism in rat brain mitochondria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 112:353–357CrossRefPubMedGoogle Scholar
  40. 40.
    Qi H, Chen HZ, Jin ZJ (2002) Caspase 3 gene expression and [Ca2 +]i homeostasis underlying desipramine-induced C6 glioma cell apoptosis. Acta Pharmacol Sin 23:803–807PubMedGoogle Scholar
  41. 41.
    Koch JM, Kell S, Aldenhoff JB (2003) Differential effects of fluoxetine and imipramine on the phosphorylation of the transcription factor CREB and cell-viability. J Psychiatr Res 37:53–59CrossRefPubMedGoogle Scholar
  42. 42.
    Xia Z, Bergstrand A, DePierre JW, Nassberger L (1999) The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol 13:338–347CrossRefPubMedGoogle Scholar
  43. 43.
    Hroudova J, Fisar Z (2010) Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro Endocrinol Lett 31:336–342PubMedGoogle Scholar
  44. 44.
    Hargreaves IP, Duncan AJ, Wu L, Agrawal A, Land JM, Heales SJ (2007) Inhibition of mitochondrial complex IV leads to secondary loss complex II-III activity: implications for the pathogenesis and treatment of mitochondrial encephalomyopathies. Mitochondrion 7:284–287CrossRefPubMedGoogle Scholar
  45. 45.
    Heales SJ, Davies SE, Bates TE, Clark JB (1995) Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem Res 20:31–38CrossRefPubMedGoogle Scholar
  46. 46.
    Canevari L, Clark JB, Bates TE (1999) beta-Amyloid fragment 25–35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett 457:131–134CrossRefPubMedGoogle Scholar
  47. 47.
    Saada A, Bar-Meir M, Belaiche C, Miller C, Elpeleg O (2004) Evaluation of enzymatic assays and compounds affecting ATP production in mitochondrial respiratory chain complex I deficiency. Anal Biochem 335:66–72CrossRefPubMedGoogle Scholar
  48. 48.
    Fromenty B, Freneaux E, Labbe G, Deschamps D, Larrey D, Letteron P, Pessayre D (1989) Tianeptine, a new tricyclic antidepressant metabolized by beta-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem Pharmacol 38:3743–3751CrossRefPubMedGoogle Scholar
  49. 49.
    Stryer L (1995) Biochemistry, 4th edn. Chapter 21: Oxidative phosphorylation. W.H. Freeman & Company, San FranciscoGoogle Scholar
  50. 50.
    Athanasiou A, Clarke AB, Turner AE, Kumaran NM, Vakilpour S, Smith PA, Bagiokou D, Bradshaw TD, Westwell AD, Fang L, Lobo DN, Constantinescu CS, Calabrese V, Loesch A, Alexander SP, Clothier RH, Kendall DA, Bates TE (2007) Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun 364:131–137CrossRefPubMedGoogle Scholar
  51. 51.
    Calabrese V, Scapagnini G, Giuffrida Stella AM, Bates TE, Clark JB (2001) Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem Res 26:739–764CrossRefPubMedGoogle Scholar
  52. 52.
    Tachibana K, Matsumoto M, Koseki H, Togashi H, Kojima T, Morimoto Y, Yoshioka M (2006) Electrophysiological and neurochemical characterization of the effect of repeated treatment with milnacipran on the rat serotonergic and noradrenergic systems. J Psychopharmacol 20:562–569CrossRefPubMedGoogle Scholar
  53. 53.
    Darley-Usmar V (2004) The powerhouse takes control of the cell; the role of mitochondria in signal transduction. Free Radic Biol Med 37:753–754CrossRefPubMedGoogle Scholar
  54. 54.
    Arnould T, Vankoningsloo S, Renard P, Houbion A, Ninane N, Demazy C, Remacle J, Raes M (2002) CREB activation induced by mitochondrial dysfunction is a new signaling pathway that impairs cell proliferation. EMBO J 21:53–63CrossRefPubMedGoogle Scholar
  55. 55.
    Parikh VS, Morgan MM, Scott R, Clements LS, Butow RA (1987) The mitochondrial genotype can influence nuclear gene expression in yeast. Science 235:576–580CrossRefPubMedGoogle Scholar
  56. 56.
    Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1116–1127CrossRefPubMedGoogle Scholar
  57. 57.
    Calabrese V, Cornelius C, Dinkova-Kostova AT, Calabrese EJ, Mattson MP (2010) Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal 13:1763–1811CrossRefPubMedGoogle Scholar
  58. 58.
    Dirnagl U, Meisel A (2008) Endogenous neuroprotection: mitochondria as gateways to cerebral preconditioning? Neuropharmacology 55(3):334–344CrossRefPubMedGoogle Scholar
  59. 59.
    Riepe MW, Ludolph AC (1997) Chemical preconditioning: a cytoprotective strategy. Mol Cell Biochem 174:249–254CrossRefPubMedGoogle Scholar
  60. 60.
    González-Pardo H, Conejo NM, Arias JL, Monleon S, Vinader-Caerols C, Parra A (2008) Changes in brain oxidative metabolism induced by inhibitory avoidance learning and acute administration of amitriptyline. Pharmacol Biochem Behav 89:456–462CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Medical Laboratory Sciences, Faculty of Allied Health SciencesThe Hashemite UniversityZarqaJordan
  2. 2.School of Biomedical Sciences, University of Nottingham Medical SchoolQueen’s Medical CentreNottinghamUK
  3. 3.New-Use Therapeutics Limited, BioCity NottinghamNottinghamUK

Personalised recommendations